The global Sarcoma Drugs Market research report 2030, as published by Data bridge Market Research, provides insights into the current global outlook and key regions, examining Major Players, Countries, Product Types, and end industries. It focuses on top players in the global market and categorizes the market based on several parameters.
This Sarcoma Drugs market research report identifies the competitive landscape of industries, offering a comprehensive understanding of international competition. The study outlines the anticipated growth of the global market during forecast period. Compiled with a blend of static and dynamic perspectives, this research report captures the essence of the businesses views.
Data Bridge Market Research analyses that the sarcoma drugs market which was USD 1222.20 million in 2022, is expected to reach USD 2435.31 million by 2030, at a CAGR of 9.00% during the forecast period 2023 to 2030.
Top Companies in the Global Sarcoma Drugs Market:
Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), among others.
Market Segmentation:
The sarcoma drugs market is segmented on the basis of type, drug therapy, drug type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Angiosarcoma
- Epithelioid Sarcoma
- Liposarcoma
- Osteosarcoma
- Soft Tissue Sarcoma
- Kaposi's Sarcoma
- Chondrosarcoma
- Dermatofibrosarcoma Protuberans
- Leiomyosarcoma
- Others
Drug Therapy
- Chemotherapy
- Doxorubicin
- Epirubicin
- Ifosfamide
- Eribulin
- Temozolomide
- Methotrexate
- Others
- Targeted therapy
- Olaratumab
- Imatinib
- Pazopanib
- Pexidartinib
- larotrectinib
- Others
- Immunotherapy
- Pembrolizumab
- Others
Drug Type
- Branded
- Lartruvo
- Gleevec
- Votrient
- Tazverik
- Turalio
- Vitrakvi
- keytruda
- Others
- Generic
End-Users
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Distribution Channel
- Direct Tender
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Geographically, the detailed analysis of consumption, revenue, market share, and growth rate of the following regions:
– Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)
– North America (United States, Mexico & Canada)
– South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)
– Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)
– Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).
North America dominates the sarcoma drugs market due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to constant rise in the incidence of cancer coupled with increased demand for cost-efficient therapeutics.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Browse The Report Description:
https://www.databridgemarketresearch.com/reports/global-sarcoma-drugs-market
Market Dynamics
Drivers
- Growing use of immunotherapy for the treatment of sarcoma
Stimulating or boosting the natural defences of a patient's immune system so that it works harder or smarter to find and attack cancer cells. Immunotherapy has recently become an important part of the treatment of certain types of cancer. New immunotherapy treatments and new ways of working with the immune system are being tested and approved at a rapid pace. Immunotherapy is more effective for some cancers than others. During the forecast period, these factors are expected to drive the growth of the sarcoma drugs market.
- Increasing Cancer Prevalence to support Sarcoma Drugs
Cancer has surpassed cardiovascular disease as the world's second leading cause of death. Environmental factors such as tobacco use, urbanization, changing dietary patterns, and an extended post-reproductive lifespan all contribute to this phenomenon. Cancer is a growing burden, according to the World Health Organization (WHO), with the number of new cancer cases expected to rise from 18.1 million in 2018 to 29.4 million by 2040. As a result, rising cancer prevalence is expected to drive demand for global oncology cancer drugs during the forecast period. Furthermore, rising cancer awareness is expected to benefit the sarcoma drugs market in the coming years.
Opportunities
- Possession of a Strong Drug Pipeline to Fuel Sarcoma Drugs
Cancer treatment is evolving at a rapid pace. The R&D pipeline is producing a slew of novel treatments, many of which are frequently combined with other new or existing medications. Many pharmaceutical companies are investing in novel cancer drug research. For instance, Pfizer acquired Array BioPharma in 2019 with the goal of expanding its oncology presence and pipeline, beginning with an approved melanoma combination therapy that is currently in a phase 3 trial for a type of metastatic colorectal cancer. This, combined with an rising preference for biosimilar and biologics entering the market, is expected to propel the sarcoma drugs market forward.
Browse Other Trending Reports:
Global Bloom Syndrome Treatment Market – Industry Trends and Forecast to 2030
https://www.databridgemarketresearch.com/reports/global-bloom-syndrome-treatment-market
Global Consumer Grade 3D Scanner Market – Industry Trends and Forecast to 2030
https://www.databridgemarketresearch.com/reports/global-consumer-grade-3d-scanner-market
Global Feed Enzymes for Livestock Market - Industry Trends and Forecast to 2029
https://www.databridgemarketresearch.com/reports/global-feed-enzymes-for-livestock-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
Contact Us:
Data Bridge Market Research
Tel: +1-888-389.80-2818 | +44 208 089 1725 | +852 8192 7475
Email: [email protected]